Johnson & Johnson (NYSE:JNJ) Reports Positive Findings In Lupus Treatment Using Pipeline Drug, Stelara


Johnson & Johnson (NYSE:JNJ) released clinical trial data for Stelara, developmental treatment drug for Lupus, revealing that the trials exhibited some significant and positive results.

Stelara which is also known as ustekinumab showcased positive results in the treatment of systemic lupus. The Johnson & Johnson revealed that the data collected from the clinical trials demonstrated a significant reduction in systemic lupus compared to the placebo during the mid-stage trials. The drug has already been approved by been approved for treating various diseases including Crohn’s disease and psoriatic, and psoriasis arthritis.

There were 102 lupus patients participating in the clinical trials for Stelara and 60 percent of them exhibited improvements in their health within the 24-week trial period. This was significant especially compared to the 31 percent of the patients who were in the placebo arm of the study amid other standard treatments.

“Any new treatment for lupus is going to be very welcomed by patients and physicians,” stated Dr. Ronald van Vollenhoven.

Dr. Vollenhoven was the lead investigator in the Stelara study and he also described the results of the clinical study as encouraging and exciting. He also highlighted the results of the trial also enforced the safety that Stelara is known for. J&J claims that the results of the study were also strong enough to push it into a more comprehensive phase 3 trials. The company also pointed out that Benlysta, a lupus treatment from rival drugmaker GlaxoSmithKline plc (ADR) (NYSE:GSK) is the only lupus treatment that has been approved over the last 50 years or so. J&J is thus excited about the trial results because they represent a chance to change that.

Roughly 1.5 million people suffer from the chronic inflammatory autoimmune disease in the U.S and about 5 million globally. However, it was not all positive news. The treatment failed to hit the mark as far as the statistical significance in comparison with the placebo in some of the secondary measures of lupus activity.

Johnson & Johnson stock closed the latest trading session on Friday at $140.08 after a 0.11 percent gain compared to the value of the stock during the previous trading session.


Please enter your comment!
Please enter your name here